摘要:
The present invention provides an anti-hepatitis C virus E2 protein antibody or antigen-binding antibody fragment thereof having infection inhibiting activity against hepatitis C virus (HCV). The present invention further provides an anti-hepatitis C virus E2 protein antibody or antigen-binding antibody fragment thereof comprising a certain variable region, which have infection inhibiting activity against hepatitis C virus (HCV) and exhibits an escape mutant emergence suppressive property.
摘要:
This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5' to 3' direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.
摘要:
The objection of the invention is to provide an antibody that inhibits infection with hepatitis C virus (HCV). To this end, this invention provides an antibody that recognizes the hepatitis C virus (HCV) particle obtained from the hepatitis C virus (HCV) genome comprising the following (i) and (ii) ligated to each other as an antigen and has an inhibitory activity on infection with hepatitis C virus (HCV): (i) (a) the 5'-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the JFH-1 strain of the hepatitis C virus (HCV) or (b) the 5'-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the J6CF strain the hepatitis C virus (HCV); and (ii) the NS2 protein-encoding sequence, the NS3 protein-encoding sequence, the NS4A protein-encoding sequence, the NS4B protein-encoding sequence, the NS5A protein-encoding sequence, the NS5B protein-encoding sequence, and the 3'-untranslated region of the JFH-1 strain.
摘要:
The present invention relates to a method for producing a recombinant hepatitis C virus-like particle comprising the steps of introducing into (i) a cell in which an RNA replicon comprising a nucleotide sequence comprising the 5' untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3' untranslated region of a genome RNA derived from a hepatitis C virus strain autonomously replicates, (ii) a vector expressing the Core, E1, E2, and p7 proteins derived from a hepatitis C virus strain that is the same as or different from that as defined in the above (i), culturing the cell, and recovering the produced virus-like particle, and a recombinant hepatitis C virus particle produced by this method.
摘要:
This invention relates to a nucleic acid comprising a nucleic acid sequence encoding an epitope tag peptide in the hypervariable region 1 of the E2 protein of naturally occurring or chimeric hepatitis C virus (HCV) genome, an epitope-tagged HCV particle encoded by such nucleic acid, and a method for purifying the HCV particles at a high purity in a simple manner with the use of an anti-epitope tag antibody-immobilized support.
摘要:
A combination of an HCV antigen for inducing an antibody having the activity of inhibiting HCV infection and an optimum adjuvant is discovered, so as to provide an effective HCV vaccine composition. The hepatitis C virus vaccine composition comprises: inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain; an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and aluminium hydroxide.
摘要翻译:发现用于诱导具有抑制HCV感染活性的抗体的HCV抗原与最佳佐剂的组合,以提供有效的HCV疫苗组合物。 丙型肝炎病毒疫苗组合物包含:灭活由丙型肝炎病毒基因组制备的感染性丙型肝炎病毒颗粒获得的灭活病毒颗粒,其含有编码NS3蛋白,NS4A蛋白,NS4B蛋白,NS5A蛋白和来源于丙型肝炎病毒JFH1菌株的NS5B蛋白的序列 ; 含有序列表中SEQ ID NO:5的未甲基化CpG的寡核苷酸; 和氢氧化铝。
摘要:
The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5' untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3' untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
摘要翻译:本发明提供经修饰的丙型肝炎病毒基因组RNA,其包含两种或更多种丙型肝炎病毒的基因组RNA部分的核苷酸序列,其包含5'非翻译区,核心蛋白编码序列,E1蛋白编码序列,p7 蛋白编码序列,E2蛋白编码序列,NS2蛋白编码序列,NS3蛋白编码序列,NS4A蛋白编码序列,NS4B蛋白编码序列,NS5A蛋白编码序列,NS5B蛋白编码序列和3' 非翻译区域,并且可以自主复制。 特别地,本发明涉及修饰的丙型肝炎病毒基因组RNA,其可通过用编码NS3的部分RNA序列取代编码丙型肝炎病毒基因组RNA的NS3,NS4,NS5A和NS5B蛋白的RNA序列部分而自主复制 ,SEQ ID NO:1所示的JFH1菌株的NS4,NS5A和NS5B蛋白。
摘要:
The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.